0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Bevacizumab and Cancer Treatment-Related Mortality—Reply

Shenhong Wu, MD, PhD; Vishal Ranpura, MD; Sanjay Hapani, MD
JAMA. 2011;305(22):2291-2293. doi:10.1001/jama.2011.760.
Text Size: A A A
Published online

Extract

In Reply: Dr Yang and colleagues identified a number of errors in our study related to incorrect data extraction. They are right, and a correction appears in this issue. We regret the errors. Overall, the final results and conclusions did not change substantially.

The goal of our study was to provide insight into the risk of FAEs related to chemotherapy associated with a biological agent, in this case bevacizumab. These events are most likely the result of serious adverse effects from the treatment, as shown in our study. We agree with Dr Punt and colleagues that many FAEs could be prevented by better adherence to treatment guidelines and adequate patient care. However, our study, being a meta-analysis, was limited in assessing these issues. The included studies did not contain any information regarding the assessment of the relationship between FAEs and treatment and major protocol violations and monitoring results.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

June 8, 2011
Zu-Yao Yang, MD; Chen Mao, MD; Jin-Ling Tang, MD, PhD
JAMA. 2011;305(22):2291-2293. doi:10.1001/jama.2011.757.
June 8, 2011
Cornelis J. A. Punt, MD, PhD; Linda Mol, MSc; Miriam Koopman, MD, PhD
JAMA. 2011;305(22):2291-2293. doi:10.1001/jama.2011.758.
June 8, 2011
Patricia B. Cerrito, PhD
JAMA. 2011;305(22):2291-2293. doi:10.1001/jama.2011.759.
CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();